[Cost-effectiveness of cancer therapy].
Under recent healthcare reforms, the urgent need for establishing evidence-based healthcare and for economic evaluation has been emphasized. Cancer not only accounts for a major burden of diseases, but also has major economic impacts on both individual patients and society. Most cancer therapies are essentially high-cost and high-technology, and provide uncertain outcomes. Concerns about the appropriate choice and utilization of cancer therapy is increasing. However, economic evaluations for cancer therapy are lacking in a number of areas, despite recent advances. In Japan, to catch up with international trends, serious efforts to generate better evidence for economic evaluation of cancer therapy have recently been made. A league table for economic evaluation of cancer therapy in Japan has been constructed, based on results including preventive antiemetic treatment, breast conserving and post-adjuvant therapy for early breast cancer, bone marrow transplantation for leukemia, interferon treatment for hepatitis C with liver cirrhosis, and others. This information shows substantial possibilities for evaluating the value-for-money of cancer therapy. This may lead to the establishment of an effective and efficient healthcare system in Japan.
Hisashige
A
A
Dept. of Preventive Medicine, School of Medicine, University of Tokushima.
D000208:Acute Disease; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D017048:Health Care Costs / Q000592:standards; D006801:Humans; D007564:Japan; D007938:Leukemia / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009313:National Health Programs / Q000191:economics* / Q000592:standards / Q000639:trends; D009369:Neoplasms / Q000191:economics*